Clinical Pipeline Pyramid™ Discovery Platform Oncology and CNS Discovery Sustaining Innovation Proprietary Products and Programs Partnered Products and Programs Phase 1Phase 2Phase 3 ASTX660 Dual Antagonist Inhibition of Apoptosis Proteins (IAPs) XIAP and cIAP (Advanced Solid Tumors and Lymphomas) . . Ownership: Astex Mechanism of Action: Dual Antagonist of Inhibitors of Apoptosis Proteins (IAPs) XIAP and cIAP Indication: Advanced Solid Tumors and Lymphomas How this therapy can help Apoptosis or programmed cell death, while part of normal cell behavior, is often altered in cancer cells and can be prevented by overexpression of anti-apoptotic proteins, such as XIAP and cIAP. These IAPs are key regulators of anti-apoptotic and pro-survival signaling pathways and their dysregulation, through overexpression or loss of endogenous antagonists, occurs in various cancers. This is associated with tumor growth, poor prognosis and resistance to treatment, making IAPs attractive targets for anticancer therapy. ASTX660 has a unique IAP antagonist molecular profile, with balanced XIAP and cIAP antagonist activity. Given the importance of XIAP in regulating both extrinsic and intrinsic apoptosis pathways, improved XIAP antagonism, as demonstrated with ASTX660 compared to other IAP antagonists in the clinic, has the potential to result in enhanced pro-apoptotic activity and tumor cell death. Clinical status ASTX660 is currently being evaluated in patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma as part of the Phase 2 portion of a Phase 1/2 study in patients with advanced solid tumors and lymphomas to determine safety, pharmacokinetics and preliminary activity ASTX660 is also being studied in combination with oral decitabine and cedazuridine in the treatment of acute myeloid leukemia (AML). View clinical studies and status View Presentations and Publications Proprietary Products and Programs Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies) Tolinapant (ASTX660) Dual IAP Antagonist (Solid Tumors & Lymphomas) ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors) ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors) Azacitidine and Cedazuridine (ASTX030) Oral DNMT inhibitor (Hematological Malignancies) TAS1440 Oral LSD1 inhibitor (Hematological Malignancies) TAS1553 Oral small molecule ribonucleotide reductase (RNR) inhibitor (Hematological Malignancies) © Astex Pharmaceuticals All rights reserved Useful links Home Sitemap Privacy Policy Terms of Use Legal Member of the Otsuka Group We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok